backtop


Print 10 comment(s) - last by PresidentThoma.. on Aug 11 at 10:32 PM


  (Source: telegraph.co.uk)
It's mainly for pre-diabetics who don't have an advanced version of the disease

A new drug could give pre-diabetics the chance to combat the onset of full-blown type 1 diabetes

The drug is called teplizumab, and it helped pre-diabetics maintain their current level of insulin production for two full years without the condition worsening. The drug seemed to be most beneficial for pre-diabetics rather than those with advanced type 1 diabetes. 

The drug was developed by Jeffrey Bluestone, PhD, an immunologist at UC San Francisco, and Mary Clausen, Distinguished Professor at UC San Francisco. The clinical trial was led by Kevan Herold, MD, PhD, a professor of immunobiology and deputy director for translational science at Yale University.

Teplizumab works by using an antibody targeted against a molecule called CD3. The antibody binds to the immune system's T-cells and stops them from attacking beta cells. This is effective because the disease is caused by the body's immune system destroying insulin-producing beta cells in the pancreas. 

"The benefits of treatment among the patients who still had moderately healthy insulin production suggests that the sooner we can detect the pre-diabetes condition and get this kind of drug onboard, the more people we can protect from the progressive damage caused by an autoimmune attack," said Bluestone. 

Those who have advanced type 1 diabetes, however, didn't seem to benefit in the clinical trial. Some even lost half or more of their ability to produce insulin, which was likely due to differences in the "metabolic condition of the patients and in the severity of their disease."

For those who are past the point of pre-diabetes, don't fret. Just earlier this year, researchers from the Universitat Autònoma de Barcelona significantly improved the blood glucose levels of dogs with type 1 diabetes through a gene therapy that consists of a single session of multiple injections. These injections presented adeno-associated vectors (AAV) that both expressed the insulin gene, and also glucokinase (an enzyme that regulates an uptake of glucose from the blood). When both genes were expressed, the excess of blood sugar in type 1 diabetic dogs was controlled over a long-term period.

Source: Science Daily



Comments     Threshold


This article is over a month old, voting and posting comments is disabled

RE: Makes sense
By DrApop on 8/8/2013 10:54:01 PM , Rating: 2
oops..."since the drug doesn't completely inhibit/block the immune attack on the immune system."

should be:
"since the drug doesn't completely inhibit/block the immune attack of the beta cells."


"Game reviewers fought each other to write the most glowing coverage possible for the powerhouse Sony, MS systems. Reviewers flipped coins to see who would review the Nintendo Wii. The losers got stuck with the job." -- Andy Marken














botimage
Copyright 2014 DailyTech LLC. - RSS Feed | Advertise | About Us | Ethics | FAQ | Terms, Conditions & Privacy Information | Kristopher Kubicki